LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
© LexDana · beta
LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
LexDanaLexDanabeta

Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

AllCopyright & Trade Secrets59Federal Circuit877ITC / Section 33788Patent Litigation216Patent Prosecution126Pharma & ANDA62PTAB686Supreme Court61Trademark158USPTO Policy78Unsorted257

Tagged 35 u.s.c. § 271(e)(2) · clear

Federal Circuit

An ANDA Specification that Directly Addresses Issues of Infringement Controls the Infringement Inquiry

PAR PHARMACEUTICAL, INC. V. EAGLE PHARMACETICALS, INC. Before Moore , Prost, and Hughes. Appeal from the United States District Court for the District of Delaware. Summary: An ANDA was held not to infringe asserted claims because the ANDA specifies pH…

August 23, 2022·Federal Circuit·1 min read
LexDana
AskSearchRankingsInsightsPricingProfileContactTermsPrivacy
The LexDana Docket
Monthly — what shipped, who moved, what we published.
© 2026 LexDana, Inc.·Powered by Patexia data